EA201690376A1 - Ингибиторы дезоксицитидинкиназы - Google Patents
Ингибиторы дезоксицитидинкиназыInfo
- Publication number
- EA201690376A1 EA201690376A1 EA201690376A EA201690376A EA201690376A1 EA 201690376 A1 EA201690376 A1 EA 201690376A1 EA 201690376 A EA201690376 A EA 201690376A EA 201690376 A EA201690376 A EA 201690376A EA 201690376 A1 EA201690376 A1 EA 201690376A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitors
- compounds
- deoxicitidinkinase
- cancer
- dck
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
В данном документе представлены соединения, которые связывают dCK, и способы лечения рака. Более конкретно, производные 2-фенилтиазола, связанные с 4,6-диаминопиримидиновым фрагментом, раскрыты как ингибиторы активности дезоксицитидинкиназы. Кроме того, представлены ингибиторы - соединения, имеющие стереоцентр. Данные соединения имеют терапевтическое применение в лечении рака.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865468P | 2013-08-13 | 2013-08-13 | |
PCT/US2014/050931 WO2015023776A2 (en) | 2013-08-13 | 2014-08-13 | Deoxycytidine kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690376A1 true EA201690376A1 (ru) | 2016-07-29 |
EA036177B1 EA036177B1 (ru) | 2020-10-09 |
Family
ID=52468801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690376A EA036177B1 (ru) | 2013-08-13 | 2014-08-13 | Ингибиторы дезоксицитидинкиназы |
Country Status (11)
Country | Link |
---|---|
US (2) | US9598404B2 (ru) |
EP (1) | EP3033340B1 (ru) |
JP (1) | JP6542216B2 (ru) |
KR (1) | KR102330566B1 (ru) |
CN (1) | CN105658648B (ru) |
AU (1) | AU2014306673B2 (ru) |
BR (1) | BR112016003019A2 (ru) |
CA (1) | CA2920738A1 (ru) |
EA (1) | EA036177B1 (ru) |
IL (1) | IL244029B (ru) |
WO (1) | WO2015023776A2 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3033340B1 (en) * | 2013-08-13 | 2019-12-04 | The Regents of The University of California | Deoxycytidine kinase inhibitors |
CA3010723A1 (en) * | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Deoxycytidine kinase binding compounds |
CN106421790B (zh) * | 2016-11-25 | 2018-12-25 | 复旦大学附属金山医院 | Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用 |
CN109134354B (zh) * | 2018-09-19 | 2022-03-25 | 天津科技大学 | 2-吡啶甲基硫醚的合成方法及相关药物的合成工艺 |
US20220133735A1 (en) | 2020-11-02 | 2022-05-05 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014657A1 (en) * | 2006-07-12 | 2008-01-17 | Beckton Dickinson And Company | Use of Albumin, Bovine, P-Aminophenyl N-Acetyl B-D Glucosaminide as a Control Line for an Immunoassay Device |
US8093246B2 (en) * | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
JP2012531435A (ja) * | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | PI3K阻害剤としての4H−ピリド[1,2−a]ピリミジン−4−オン誘導体 |
BR112013020329A2 (pt) * | 2011-02-09 | 2016-08-02 | Hoffmann La Roche | compostos heterocíclicos como inibidores da pi3-quinase |
WO2012122368A1 (en) * | 2011-03-08 | 2012-09-13 | The Regents Of The University Of California | Deoxycytidine kinase binding compounds |
EP2518071A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
US20130123281A1 (en) * | 2011-11-11 | 2013-05-16 | Beta Cat Pharmaceuticals, Llc | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules |
EP3033340B1 (en) * | 2013-08-13 | 2019-12-04 | The Regents of The University of California | Deoxycytidine kinase inhibitors |
-
2014
- 2014-08-13 EP EP14836561.2A patent/EP3033340B1/en active Active
- 2014-08-13 WO PCT/US2014/050931 patent/WO2015023776A2/en active Application Filing
- 2014-08-13 JP JP2016534818A patent/JP6542216B2/ja active Active
- 2014-08-13 KR KR1020167006675A patent/KR102330566B1/ko active IP Right Grant
- 2014-08-13 CN CN201480055864.1A patent/CN105658648B/zh active Active
- 2014-08-13 BR BR112016003019A patent/BR112016003019A2/pt not_active Application Discontinuation
- 2014-08-13 CA CA2920738A patent/CA2920738A1/en not_active Abandoned
- 2014-08-13 EA EA201690376A patent/EA036177B1/ru not_active IP Right Cessation
- 2014-08-13 AU AU2014306673A patent/AU2014306673B2/en active Active
-
2016
- 2016-01-11 US US14/992,396 patent/US9598404B2/en active Active
- 2016-02-08 IL IL24402916A patent/IL244029B/en active IP Right Grant
-
2017
- 2017-01-31 US US15/421,258 patent/US9981961B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR102330566B1 (ko) | 2021-11-25 |
EP3033340A4 (en) | 2017-01-25 |
EP3033340A2 (en) | 2016-06-22 |
AU2014306673B2 (en) | 2018-12-06 |
EA036177B1 (ru) | 2020-10-09 |
BR112016003019A2 (pt) | 2017-09-12 |
JP2016530266A (ja) | 2016-09-29 |
KR20160058785A (ko) | 2016-05-25 |
CN105658648A (zh) | 2016-06-08 |
WO2015023776A2 (en) | 2015-02-19 |
JP6542216B2 (ja) | 2019-07-10 |
IL244029B (en) | 2019-10-31 |
CN105658648B (zh) | 2020-03-17 |
CA2920738A1 (en) | 2015-02-19 |
US9981961B2 (en) | 2018-05-29 |
WO2015023776A3 (en) | 2015-11-12 |
US20160237076A1 (en) | 2016-08-18 |
US20170204090A1 (en) | 2017-07-20 |
US9598404B2 (en) | 2017-03-21 |
IL244029A0 (en) | 2016-04-21 |
EP3033340B1 (en) | 2019-12-04 |
AU2014306673A1 (en) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
MX2016007801A (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
EA201890754A1 (ru) | Соединения и способы их применения | |
BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
MX362215B (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
EA201590997A1 (ru) | Соединения и способы их применения | |
EA201690206A1 (ru) | Терапевтически активные соединения и способы их применения | |
EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
PH12017500215A1 (en) | Protein kinase c inhibitors and methods of their use | |
MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
MX2016009663A (es) | Derivados de icariina. | |
TR201901348T4 (tr) | Metap-2 inhibitörleri olarak pirolidinon türevleri. | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
EA201791933A1 (ru) | Ингибирование активности olig2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |